Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutide
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutide. / Vedtofte, Louise; Knop, Filip K.; Vilsboll, Tina.
I: Expert Review of Clinical Pharmacology, Bind 8, Nr. 3, 01.05.2015, s. 273-282.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutide
AU - Vedtofte, Louise
AU - Knop, Filip K.
AU - Vilsboll, Tina
N1 - Publisher Copyright: © Informa UK, Ltd.
PY - 2015/5/1
Y1 - 2015/5/1
N2 - Insulin therapy in the management of Type 2 diabetes is often postponed and/or not adequately intensified to maintain glycemic control because of the risk of weight gain and hypoglycemia. A fixed combination of the long-acting insulin degludec and liraglutide has recently been accepted by the EMA for the management of Type 2 diabetes. The incentive for this combination is to exploit the advantages of each of the drugs while counterbalancing the side effects. Insulin degludec effectively reduces fasting plasma glucose, but carries the risk of hypoglycemia and body weight gain. Liraglutide, on the other hand, exerts glycemic control with a minimal risk of hypoglycemia and, at the same time, reduces appetite and body weight.
AB - Insulin therapy in the management of Type 2 diabetes is often postponed and/or not adequately intensified to maintain glycemic control because of the risk of weight gain and hypoglycemia. A fixed combination of the long-acting insulin degludec and liraglutide has recently been accepted by the EMA for the management of Type 2 diabetes. The incentive for this combination is to exploit the advantages of each of the drugs while counterbalancing the side effects. Insulin degludec effectively reduces fasting plasma glucose, but carries the risk of hypoglycemia and body weight gain. Liraglutide, on the other hand, exerts glycemic control with a minimal risk of hypoglycemia and, at the same time, reduces appetite and body weight.
KW - Basal insulin
KW - DUAL I
KW - DUAL II
KW - fixed combination
KW - GLP-1RA
KW - IDegLira
KW - incretin mimetic
KW - insulin degludec
KW - liraglutide
KW - Type 2 diabetes
UR - http://www.scopus.com/inward/record.url?scp=84928618601&partnerID=8YFLogxK
U2 - 10.1586/17512433.2015.1029455
DO - 10.1586/17512433.2015.1029455
M3 - Review
C2 - 25816888
AN - SCOPUS:84928618601
VL - 8
SP - 273
EP - 282
JO - Expert Review of Clinical Pharmacology
JF - Expert Review of Clinical Pharmacology
SN - 1751-2433
IS - 3
ER -
ID: 305734696